A 60-year-old with MASLD and T2D wants to know risk-reducing strategies. Which has proven benefit for liver and cardio-renal outcomes in CKD/diabetes?...

Question

A 60-year-old with MASLD and T2D wants to know risk-reducing strategies. Which has proven benefit for liver and cardio-renal outcomes in CKD/diabetes?

Accepted Answer

SGLT2 inhibitor therapy

Answer

Niacin therapy

Answer

Cholestyramine

Answer

High-dose vitamin E regardless of fibrosis

Answer

No pharmacotherapy useful

us-abim MCQ (SBA): MASLD with Diabetes/CKD

A 60-year-old with MASLD and T2D wants to know risk-reducing strategies. Which has proven benefit for liver and cardio-renal outcomes in CKD/diabetes?